Potential use of rapamycin in HIV infection

British Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2010, Pages 784-793

  Donia, Marco ^a   McCubrey, James A ^b   Bendtzen, Klaus ^c   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b EAST CAROLINA UNIVERSITY   (United States)

^c Rigshospitalet   (Denmark)

Author keywords

CCR5; HIV; MTOR; Rapamycin

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5; DEFOROLIMUS; ENFUVIRTIDE; EVEROLIMUS; IBALIZUMAB; INCB 009471; MARAVIROC; PEGINTERFERON; RALTEGRAVIR; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TEMSIROLIMUS; TMB 355; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MEDICAL LITERATURE; MONOTHERAPY; MUCOSA INFLAMMATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; THROMBOCYTE FUNCTION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; MICE; SIROLIMUS; TRANSLATIONAL RESEARCH; VIRUS REPLICATION;

EID: 78349247944     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03735.x     Document Type: Article

References (67)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6.
2. Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO. Considerations in sirolimus use in the early and late post-transplant periods. Expert Opin Drug Saf 2009; 8: 421-34.
3. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008; 8: 647-65.
4. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 3: 335-40.
5. Bai X, Jiang Y. Key factors in mTOR regulation. Cell Mol Life Sci 2010; 67: 239-53.
6. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82: 381-8.
7. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25: 6436-46.
8. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst D. Sabatini DM. Rictor a novel binding partner of mTOR, defines the rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
9. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolong rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
10. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mulholland DJ, Magnusson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15: 148-59.
11. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-70.
12. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
13. Zeng Z, Sarbassov DD, Samudio IJ, Yee KW, Munsell MF, Jackson CE, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit Akt activation in AML. Blood 2006; 109: 3509-12.
14. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 2009; 7: 645-56.
15. Fouladi M, Luningham F, Wu J, O'Shaughnessy MO, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25: 4806-12.
16. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic towards cancer therapy. Mol Cancer Ther 2009; 8: 1-9.
17. Brachmann S, Fritsch C, Maria SMM, Garcia-Echeverria C. PI3K and mTOR inhibitors- a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009; 21: 194-8.
18. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase- moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
19. Taiwo B, Hicks C, Eron J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother 2010; 65: 1100-7.
20. McKinnell JA, Saag MS. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. Curr Opin HIV AIDS 2009; 4: 513-7.
21. Copeland KF. Inhibition of HIV-1 entry into cells. Recent Pat Antiinfect Drug Discov 2006; 1: 107-12.
22. Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS 2009; 4: 150-8.
23. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30: 1228-50.
24. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
25. Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010; 44: 145-56.
26. Marr P, Walmsley S. Reassessment of enfuvirtide's role in the management of HIV-1 infection. Expert Opin Pharmacother 2008; 9: 2349-62.
27. Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, True AL. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antivir Ther 2006; 11: 935-9.
28. Latinovic O, Kuruppu J, Davis C, Le N, Heredia A. Pharmacotherapy of HIV-1 infection: focus on the CCR5 antagonist maraviroc. Clin Med Ther 2009; 1: 1497-510.
29. Kümmerle T, Lehmann C, Hartmann P, Wyen C, Fätkenheuer G. Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opin Investig Drugs 2009; 18: 1773-85.
30. Cohen C, DeJesus E, Mills A, Pierone G Jr, Kumar P, Ruane P, Elion R, Fusco G, Levy R, Solomon K, Erickson-Viitanen S. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy. 4th IAS Conference on AIDS Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney, Australia (Abstract TUAB106).
31. PRO 140 by IV administration in adults with HIV-1 infection. Sponsor: Progenics Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT00613379. Available at (last accessed 29 March 2010).
32. Lalezari J, Yadavalli GK, Para M, Richmond G, Dejesus E, Brown SJ, Cai W, Chen C, Zhong J, Novello LA, Lederman MM, Subramanian GM. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197: 721-7.
33. Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (TMB-202). Sponsor: TaiMed Biologics Inc. ClinicalTrials.gov Identifier: NCT00784147. Available at (last accessed on 16 July 2010).
34. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004; 48: 423-9.
35. Hladik F, Lentz G, Delpit E, McElroy A, McElrath MJ. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype. J Immunol 1999; 163: 2306-13.
36. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96: 5215-20.
37. Reynes J, Portales P, Segondy M, Baillat V, André P, Réant B, Avinens O, Couderc G, Benkirane M, Clot J, Eliaou JF. Corbeau P CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000; 181: 927-32.
38. Reynes J, Baillat V, Portales P, Clot J, Corbeau P. Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy. JAMA 2004; 291: 46.
39. Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008; 105: 20476-81.
40. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100: 10411-6.
41. Roy J, Paquette JS, Fortin JF, Tremblay MJ. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 2002; 46: 3447-55.
42. Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol 2004; 34: 1705-14.
43. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
44. Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res 2009; 83: 86-9.
45. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008; 52: 858-65.
46. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2007; 51: 2489-96.
47. Gilliam BL, Heredia A, Devico A, Le N, Bamba D, Bryant JL, Pauza CD, Redfield RR. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007; 21: 2108-10.
48. Nicoletti F, Lapenta C, Donati S, Spada M, Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin Exp Immunol 2009; 155: 28-34.
49. Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 2010; 89: 733-8.
50. Moreno A, Bárcena R, Quereda C, Casado JL, Pérez-Elías MJ, Fortún J, Nuño J, Arranz I, Moreno S. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008; 22: 547-8.
51. Mannová P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005; 79: 8742-9.
52. Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, Kato N, Eguchi K. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol 2009; 44: 856-63.
53. Rapamune package insert 2002, Wyeth.
54. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109: 681-8.
55. Romanelli F, Hoven AD. Use of virostatics as a means of targeting human immunodeficiency virus infection. Curr Pharm Des 2006; 12: 1121-7.
56. Zolopa AR. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res 2010; 85: 241-4.
57. Björndal A, Sönnerborg A, Tscherning C, Albert J, Fenyö EM. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999; 15: 647-53.
58. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81: 10209-19.
59. Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N; AIDS Clinical Trials Group 334 Investigators. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002; 29: 356-62.
60. Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
61. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 2009; 29: 1172-8.
62. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 2009; 41: 3796-9.
63. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-20.
64. Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000; 22 (Suppl. B): B93-100.
65. Bickel M, Anadol E, Vogel M, Hofmann WP, Von Hentig N, Kuetscher J, Kurowski M, Moench C, Lennemann T, Lutz T, Bechstein WO, Brodt HR, Rockstroh J. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010; 65: 999-1004.
66. Minces LR, McGowan I. Advances in the development of microbicides for the prevention of HIV infection. Curr Infect Dis Rep 2010; 12: 56-62.
67. Abdool Karim SS. Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiol 2010; 5: 527-9.